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A rapid and specific high-performance liquid chromatography method with UV detection (HPLC-UV) for the
simultaneous determination of 12 beta-lactam antibiotics (amoxicillin, cefepime, cefotaxime, ceftazidime,
ceftriaxone, cloxacillin, imipenem, meropenem, oxacillin, penicillin G, piperacillin, and ticarcillin) in small
samples of human plasma is described. Extraction consisted of protein precipitation by acetonitrile. An
Atlantis T3 analytical column with a linear gradient of acetonitrile and a pH 2 phosphoric acid solution was
used for separation. Wavelength photodiode array detection was set either at 210 nm, 230 nm, or 298 nm
according to the compound. This method is accurate and reproducible (coefficient of variation [CV] < 8%),
allowing quantification of beta-lactam plasma levels from 5 to 250 g/ml without interference with other
common drugs. This technique is easy to use in routine therapeutic drug monitoring of beta-lactam antibiotics.
The beta-lactam antibiotics constitute the most important
family of antimicrobial agents, both in terms of the large num-
ber of compounds available and in terms of prescription vol-
ume. Until recently, beta-lactams were not considered strong
candidates for therapeutic drug monitoring (TDM), as they are
assumed to have a wide therapeutic index and the most fre-
quent adverse effects involve non-dose-related allergic reac-
tions. But concepts are changing, and several studies demon-
strate the advantage of TDM for these antibiotics (4, 32).
Clinicians and pharmacologists agree that certain adverse
events like encephalopathy, seizure, and pseudolithiasis occur
when doses are excessive (2, 8, 12, 15, 16, 19, 23, 27). Various
infectious diseases, e.g., endocarditis, meningitis, and osteomy-
elitis, require administration of high-dose antibiotics via inter-
mittent or continuous infusion (6, 36, 38). Knowledge of the
antibiotic plasma concentrations, combined with bacterial sus-
ceptibility evaluated in terms of the MIC, would enable treat-
ment efficacy to be optimized while limiting the risk of dose-
related adverse effects and avoiding suboptimal concentrations
(32). The pharmacokinetics of beta-lactams can be highly vari-
able depending on the clinical situation, leading to unpredict-
able plasma concentrations. Critically ill patients with severe
infection demonstrate unusual volumes of distribution and
half-lives of drugs (3, 26). Similarly, pharmacokinetic proper-
ties are altered in severely burned patients, who have a high
risk of infection (20, 28). Plasma concentrations are also dif-
ficult to predict in patients with renal failure who require dose
adjustments (22).
There are several proposed methods for assaying beta-lac-
tams in biological fluids, either for a particular compound (5,
11, 24, 30) or for a group of compounds (9, 10, 13, 17, 18, 21,
29, 33, 34). Many other methods were developed for food
industry and agriculture applications (1). The method previ-
ously published by McWhinney et al. (25) has been validated
for 12 compounds but used three different mobile phases to
separate the compounds. A beta-lactam assay for TDM must
be robust and rapid, providing reliable results that can be
reported to the clinical ward within a few hours. A single
process simplifies the implementation of TDM for the thera-
peutic group of beta-lactam antibiotics, which includes a large
number of compounds. In this context, the simultaneous de-
termination of plasma concentrations of the beta-lactams most
commonly administered intravenously at high doses in patients
with severe infections would be most welcome.
The aim of this work was to develop a precise, reproducible,
and rapid high-performance liquid chromatography (HPLC)
method applicable for TDM of the most commonly prescribed
beta-lactams: six penicillins (amoxicillin, cloxacillin, oxacillin,
penicillin G, piperacillin, and ticarcillin), four expanded-spec-
trum cephalosporins (cefepime, cefotaxime, ceftazidime, and
ceftriaxone), and two carbapenems (imipenem and mero-
penem).
MATERIALS AND METHODS
Chemicals. Amoxicillin, ceftriaxone, cloxacillin sodium salt, and oxacillin so-
dium salt were purchased from Sigma (Saint-Quentin, France). Cefotaxime so-
dium salt, penicillin G potassium salt, and piperacillin sodium salt were pur-
chased from ICN Biomedicals (Orsay, France). Imipenem was kindly provided
by Merck and Co. (Paris, France). Ceftazidime and ticarcillin were supplied by
GlaxoSmithKline (Marly-Le-Roi, France), cefepime was supplied by Bristol-
Myers Squibb (Rueil-Malmaison, France), and meropenem was supplied by
AstraZeneca (Rueil-Malmaison, France). Acetonitrile, from Carlo Erba Re-
agenti (Val de Reuil, France), was of HPLC grade. Phosphoric acid (85%) was
purchased from Merck (Nogent-sur-Marne, France). Milli-Q water (Saint-Quen-
tin, France) was used throughout the experimentations.
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FIG. 1. HPLC chromatograms of an internal quality control with 10 g/ml of each antibiotic at 298 nm (a), 230 nm (b), and 210 nm (c). Values
after the antibiotic names are retention times.
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Instrumentation and chromatographic conditions. The HPLC system in-
cluded a P1000XR pump equipped with a degasser, an AS3000 refrigerated
autosampler, and a UV microarray spectrophotometer detector (UV6000LP;
ThermoFisher Scientific, Villebon sur Yvette, France). The compounds were
separated on an Atlantis T3 analytical column (150 by 4.6 mm, 5 m; Waters,
Saint Quentin, France), coupled with an Atlantis T3 guard column (20 by 4.6
mm, 5 m; Waters, Saint Quentin, France). The mobile phase, filtered and
degassed, consisted of a 10 mM phosphoric acid solution, adjusted to pH 2 with
hydrochloric acid, and acetonitrile. A linear gradient from 7% to 19% acetoni-
trile in 6 min and 19% to 49% from 6 to 16 min was used with a flow rate of 2
ml/min. Run time was prolonged to 22 min to return to initial conditions. The
effluent was monitored at 210 nm for cloxacillin, oxacillin, penicillin G, pipera-
cillin, and ticarcillin, at 230 nm for amoxicillin, cefepime, ceftazidime, cefo-
taxime, and ceftriaxone, and at 298 nm for imipenem and meropenem. Data were
recorded with ChromQuest software (version 2.5.1). Quantification was based on
the peak height of each compound; baselines were inspected visually and ad-
justed manually when necessary.
Standard solutions and QC materials. Stock solutions of each beta-lactam
were prepared at 50 or 100 mg/ml in water and stored at 80°C. Under these
conditions they are stable for a few months (9, 18, 25). They were further mixed
in water to obtain a 1-mg/ml solution, which was used to produce standard
solutions at 250, 125, 40, and 10 g/ml. Three working solutions of beta-lactams
at 50, 1,000, and 2,000 g/ml were prepared from stock solutions and diluted
10-fold in blank plasma to obtain quality control (QC) materials at 5 g/ml, 100
g/ml, and 200 g/ml.
Sample preparation. Venous blood samples were collected in heparinized
tubes, immediately transported on ice to the laboratory, and centrifuged for 10
min at 3,000  g and 4°C. If necessary, the plasma samples were stored at 20°C
until analysis. For the extraction procedure, 200 l of water and 700 l of
acetonitrile were added to 100 l of control or patient plasma samples. For the
calibration curve, 100 l of corresponding working solution, 100 l of water, and
700 l of acetonitrile were mixed with 100 l of blank plasma. Each sample was
vortex mixed and centrifuged at 3,000  g for 10 min at 4°C. One hundred
microliters of the supernatant was diluted with 900 l of water, and 20 l was
injected into the HPLC system. This dilution provides the same percentage of
acetonitrile in the injected sample as the initial conditions of the linear gradient.
Method validation. The method was validated according to the acceptance
criteria of industrial guidance for bioanalytical method validation (14).
Specificity and selectivity. Specificity and selectivity were measured by an-
alyzing six different blank plasma samples. Different plasma samples contain-
ing 39 frequently prescribed drugs were analyzed to investigate potential
interferences. The drugs were acetaminophen, amikacin, amiodarone, amlo-
dipine, amphotericin B, amprenavir, carbamazepine, ciprofloxacin, clonaz-
epam, digoxin, disopyramide, doripenem, doxapram, efavirenz, ertapenem,
flunitrazepam, gentamicin, indinavir, itraconazole, lopinavir, mycophenolic
acid, nelfinavir-M8, nevirapine, phenobarbital, phenytoin, propranolol,
ritonavir, saquinavir, quinine, ofloxacin, ramipril, ranitidine, salicylic acid,
sulfamethoxazole, tacrolimus, theophylline, trimethoprim, valproic acid, and
vancomycin.
Precision and accuracy. The recommended value for precision and accuracy is
15%, except for the lower limit of quantification (LOQ), for which a limit of
20% is acceptable. The limit of detection (LOD) is defined as the first con-
centration with a peak height of at least three times the baseline value. To test
within-day and between-day reproducibility, six aliquots of each QC sample were
tested the same day to evaluate within-day reproducibility and once a day for 3
days to evaluate between-day reproducibility. Mean and standard deviation (SD)
were calculated. The coefficient of variation (CV) was used to calculate precision,
and the bias was used to express accuracy (7).
Recovery. The recovery of each compound was calculated at three concentra-
tions, 10, 100, and 250 g/ml, by comparing the beta-lactam peak heights of
extracted QC samples to the beta-lactam peak heights of nonextracted standard
solutions at the same concentration.
Stability. The stability of the different antibiotics was tested on the same
extraction dilution at the beginning and at the end of the injection sequence, i.e.,
an interval of 15 h, at 9°C. The stability of beta-lactams was also determined in
patients’ plasma preserved at 4°C or room temperature for 12 h.
RESULTS AND DISCUSSION
Chromatography. Separation of the 12 compounds was sat-
isfactory, as shown in Fig. 1. No interference with endogenous
compounds was observed, allowing use of specific wavelengths
of 210, 230, and 298 nm, as shown in Fig. 2 (blank plasma
sample) and Fig. 3 (patient plasma samples). Deviation from
the baseline is related to the gradient of acetonitrile, which
absorbs UV. So the baseline absorbance was higher when the
acetonitrile amount increased. The Atlantis T3 column en-
FIG. 2. HPLC chromatograms of a blank plasma sample at 298 nm
(a), 230 nm (b), and 210 nm (c). Retention times for the different
compounds are indicated by the positions of the names.
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abled a simplified HPLC method allowing good retention of
polar drugs. A gradient of acetonitrile enabled elution of less-
polar compounds. This was the only column we know allowing
good separation of all compounds and supporting this extreme
pH. With other C18 columns, retention times ranged from 1
min (passage through the column without retention) to above
1 h (cloxacillin) and separation was not optimal. The pH of the
mobile phase was another parameter that modified retention
time. Changes in retention times of the different compounds
according to pH of the mobile phase are shown in Fig. 4. The
curve shows that extreme pH (2) provided the best separation
while maintaining retention times under 17 min. For most of
the compounds, retention time decreased as the pH increased,
with the risk of elution with the solvent front or coelution of
several compounds (penicillin G plus piperacillin at pH 5 or
amoxicillin plus ceftazidime plus ceftriaxone at pH 7). We
found the best compromise between stationary phase and pH.
In this way, the 12 antibiotics were assayed within 22 min. We
recommend the use of a guard column to extend the lifetime of
the column subjected to acid pH. At this pH, imipenem pre-
FIG. 3. Chromatograms of extracted plasma samples from patients treated with amoxicillin (residual concentration, 33.5 mg/liter) (a) and
cloxacillin (residual concentration, 15.3 mg/liter) (b).
FIG. 4. Retention times of beta-lactam antibiotics by pH of the mobile phase.
4876 VERDIER ET AL. ANTIMICROB. AGENTS CHEMOTHER.
sented 2 peaks because of its tautomeric form (31). We at-
tempted to stabilize our samples and the stock solutions by
diluting with MES (morpholineethanesulfonic acid) buffer at
pH 7.4 or phosphate buffer at pH 10 but were unable to avoid
this double peak. However, we noticed that this tautomeric
form was stable, and the accuracy and precision assays con-
firmed that we could determine the plasma concentration of
imipenem under these conditions by considering the first of the
two peaks.
Sample preparation. Different types of sample preparation
were tested, solid phase extraction (SPE) with three different
stationary phases (SCX, NH2, and OASIS HLB; Waters, St
Quentin, France) and protein precipitation. SPE was not ef-
fective for the 12 compounds. Protein precipitation was the
most reproducible and allowed the best recovery. As per-
formed by McWhinney et al. (25), we removed lipid-soluble
components by a chloroform or hexane wash after protein
precipitation. The procedure with chloroform increased the
LOQ while concentrating the compounds in the aqueous
phase, but it increased the signal-to-noise ratio and induced
some high interfering peaks. The procedure with hexane did
not change anything. This wash was not added to the extraction
procedure, so our method is extremely rapid.
Method validation. Values for retention time, detection
wavelength, linear regression, correlation coefficient, and ex-
traction recovery for the different compounds are given in
Table 1.
The calibration curves, fitted using linear regression between
the beta-lactam peak heights and the concentrations of the re-
spective compounds, appeared linear from 2 to 250 g/ml for
amoxicillin, cefepime, cefotaxime, ceftazidime, imipenem, and
meropenem and from 5 to 250 g/ml for ceftriaxone, cloxacillin,
oxacillin, penicillin G, piperacillin, and ticarcillin. All calibration
curves were well described using a weighted least-squares regres-
sion (weighting factor: 1/concentration) to achieve homogeneity
of variances. The coefficients of determination (R2) were all
above 0.99.
Specificity and selectivity. There was no evidence of inter-
ference with the different compounds tested. Not all the beta-
lactam metabolites were available and could be evaluated.
Therefore, few metabolites were verified, and one of them,
desacetyl-cefotaxime, was determined in another run because
of a risk of interference with amoxicillin or ceftazidime (reten-
tion time  3.8 min) (34). This interference was a problem for
standard solutions and QC but not in patients treated with
cefotaxime, amoxicillin, or ceftazidime. Beta-lactams are anti-
biotics which are very rarely prescribed simultaneously. Pa-
tients treated with cefotaxime present detectable concentra-
tions of desacetyl-cefotaxime but are never simultaneously
treated with amoxicillin or ceftazidime. Conversely, patients
treated with amoxicillin or ceftazidime are never treated with
cefotaxime at the same time. Currently, determination of de-
sacetyl-cefotaxime is not routinely prescribed in our hospital.
Accuracy and precision. The LODs were 1 g/ml for
amoxicillin, cefepime, cefotaxime, ceftazidime, imipenem, and
meropenem and 2 g/ml for the other compounds. The LOQ
was 2 or 5 g/ml for the different compounds. Data on the
accuracy and precision analysis are summarized in Table 2. All
the repeatability and reproducibility tests give a variation of
less than 8%.
Target residual concentrations were within the 10 to 50
g/ml range and were 30 to 100 g/ml for piperacillin and
ticarcillin (13, 17, 20, 28, 32). The efficacy of beta-lactams was
proved for plasma concentrations over 4 to 5 times greater
than the MIC more than 50% of the time between two injec-
tions. Clinicians asked for the determination in severe infec-
tions, for which they request concentrations above 10 times the
MIC 100% of the time. MICs for strains sensitive to beta-
lactams are between 0.5 and 8 g/ml. When the residual
concentration is lower than 4 times this value, the antibiotic is
no longer sufficiently effective. We concluded that it was not
necessary to determine concentrations lower than 2 or 5 g/ml
for this application.
Recovery. Mean recovery values were greater than 90% for
the different compounds.
Stability. The stability study, performed on extracts pre-
served in a refrigerated automatic injector for 15 h at 9°C,
demonstrated a reduction in spike height from 3 to 18% de-
pending on the antibiotic. Ceftazidime exhibited the most pro-
nounced degradation pre- and postextraction: in plasma pre-
served at 4°C or room temperature, concentrations declined
3.7 and 7%, respectively, after 12 h.
Therapeutic drug monitoring. Every day we receive 1 or
more requests for TDM of several beta-lactams, hence the





(y  ax  b) value for: R2
Recovery (%) at concn (g/ml) of:
a b 10 100 250
Imipenem 298 1.9 0.01085 0.10 0.9998 87.3 93.4 95.6
Cefepime 230 2.3 0.00205 0.02 0.9930 118.4 98.3 98.5
Amoxicillin 230 3.4 0.00249 0.03 0.9945 99.3 100.2 101.1
Ceftazidime 230 4.2 0.00198 0.17 0.9991 98.2 96.3 97.4
Meropenem 298 4.8 0.00186 0.46 0.9999 114.7 101.7 100.3
Ceftriaxone 230 5.9 0.00129 0.23 0.9917 98.7 98.6 97.2
Cefotaxime 230 6.8 0.00207 0.07 0.9943 100.0 99.3 100.3
Ticarcillin 210 11.3 0.00960 0.36 0.9988 104.5 102.7 100.3
Piperacillin 210 12.8 0.00407 0.40 0.9969 102.9 102.7 102.7
Penicillin G 210 13.5 0.02605 0.39 0.9952 96.9 100.9 102.2
Oxacillin 210 15.5 0.00205 0.05 0.9995 104.9 101.9 102.4
Cloxacillin 210 16.5 0.00021 0.33 0.9979 103.2 102.9 103.3
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importance of having a unique technique to be able to meet
these requests whatever the compound. During the past 18
months, 2,196 measurements (30 per week) have been per-
formed in our laboratory on these 12 drugs for 761 patients.
Amoxicillin and cloxacillin were the two beta-lactam agents
most determined. Samples were drawn at steady state to de-
termine trough concentration for intermittent administrations
or plateau concentration for continuous infusions. Analyses
performed in response to the first requests for plasma concen-
trations (n  746) showed that 15.3% of patients had inade-
quate concentrations, either 10 g/ml or 	100 g/ml, for all
compounds included. The limit of 10 g/ml was established
based on MIC breakpoints of most strains involved (35), and
the limit of 100 g/ml was set as the threshold for toxicity.
Based on our clinical experience, effective and nontoxic con-
centrations are mostly between 10 and 50 g/ml and up to 100
g/ml for piperacillin and ticarcillin, whose MIC breakpoints
are higher. Considering this range, 35.0% of patients showed
inadequate plasma concentrations, whatever the administra-
tion schedule and despite doses adapted according to weight
and renal function. Target concentrations have to be precisely
determined for each patient, depending on the strain and MIC,
consistent with the recommendations of the French Society for
Microbiology (35). Because plasma concentrations of beta-
lactams remain largely unpredictable, TDM of these antibiot-
ics is now an everyday tool, in addition to antimicrobial sus-
ceptibility testing of each strain, for the proper management of
patients receiving high intravenous doses.
Conclusion. A rapid, robust, and specific HPLC method
with UV detection for the simultaneous determination of 12
beta-lactams in small samples of human plasma is described.
Daily, this method can be applied to meet all requests in a
single sequence run. Compared with other analytical methods
published previously, the method presented here offers the
advantage of a rapid simultaneous assay of commonly pre-
scribed antibiotics using one rapid extraction protocol and
satisfying all validation criteria. It is complementary to the
method published by McWhinney et al. (25) because it does
not concern the same compounds.
In clinical practice, this technique is already in routine use
for TDM (37). Around 30 assays of beta-lactam concentrations
have been performed each week on patient plasma since the
validation. In addition, this method will be applied to more-
recent beta-lactams such as ertapenem and doripenem.
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